Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  BIOLASE Inc    BIOL

News SummaryMost relevantAll newsSector newsTweets 

BIOLASE Inc : BIOLASE Expects to Report Positive Cash Flow From Operations for Q4 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
01/22/2013 | 02:44pm CEST
BIOLASE Expects to Continue to Generate Positive Cash Flow From Operations for 2013 Overall

IRVINE, CA -- (MARKETWIRE) -- 01/22/13 -- BIOLASE, Inc. (NASDAQ: BIOL), the world's leading dental laser manufacturer and distributor, announced today that based on preliminary unaudited financial results, the Company expects to report that it generated positive cash flow from operations for Q4 2012.

"We are pleased with our preliminary unaudited financial results for Q4 2012. It is rewarding to see that our restructuring efforts over the past two years have enabled us to turn the Company around and that we are making significant progress toward achieving our financial goals," said Federico Pignatelli, Chairman and CEO. "The trends we are seeing in the adoption of dental lasers also give us confidence in achieving continued double-digit growth of our core dental franchise. Based on our current plans, we expect the Company will continue to generate positive cash flow from operations for the overall year ending December 31, 2013."

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate approximately 290 patented and patent-pending technologies designed to provide biological treatment and clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment and CAD/CAM systems. BIOLASE has sold more than 21,000 lasers.

Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolaseinc, Twitter at twitter.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

For further information, please contact:
Lisa Wilson
In-Site Communications, Inc.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOLASE INC
04/26 BIOLASE : reg; to Host 2017 First Quarter Financial Results Conference Call on M..
04/20 BIOLASE, INC : Material Modification to Rights of Security Holders, Amendments t..
04/14 BIOLASE, INC : Entry into a Material Definitive Agreement, Unregistered Sale of ..
04/13 BIOLASE : to Raise $10.5 Million from Institutional and Individual Investors in ..
03/28 BIOLASE : Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
03/23 BIOLASE : Announces Inducement Grant under NASDAQ Listing Rule 56354
03/20 BIOLASE : to Showcase Two New Game-Changing Products at International Dental Sho..
03/16 BIOLASE : to Present at the 29th Annual ROTH Conference
03/14 BIOLASE, INC. (NASDAQ : BIOL) Files An 8-K Regulation FD Disclosure
03/14 BIOLASE, INC : Regulation FD Disclosure, Financial Statements and Exhibits (form..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
04/24DJPHILIPS : Net Profit Leaps; Backs Full Year Guidance
04/10DJCorrections & Amplifications -- WSJ
03/28DJPHILIPS : to Buy Australian pharmacy Sleep Services Firm
02/09 Infineon, Cree warn U.S. might block Wolfspeed deal
02/02 EU probes online sales in electronics, video games, hotels
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
04/13 BIOLASE to raise $10.5M in a private placement
03/14 BIOLASE (BIOL) Presents At 29th Annual ROTH Conference
03/13 BIOLASE names sales chief for Americas
03/08 BIOLASE's (BIOL) CEO Harold Flynn on Q4 2016 Results - Earnings Call Transcri..
03/08 Biolase reports Q4 results
Financials ($)
Sales 2017 55,4 M
EBIT 2017 -12,6 M
Net income 2017 -12,5 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 -
Capi. / Sales 2017 1,56x
Capi. / Sales 2018 -
Capitalization 86,6 M
More Financials
Duration : Period :
BIOLASE Inc Technical Analysis Chart | BIOL | US0909111082 | 4-Traders
Full-screen chart
Technical analysis trends BIOLASE INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus BUY
Number of Analysts 2
Average target price 2,50 $
Spread / Average Target 95%
Consensus details
Harold C. Flynn President, Chief Executive Officer & Director
Paul N. Clark Chairman
Richard R. Whipp Vice President-Operations
Mark Joseph Nelson Chief Financial Officer
Dmitri Boutoussov Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PHILIPS10.31%32 224
More Results